Comparative Pharmacology
Head-to-head clinical analysis: COLESEVELAM HYDROCHLORIDE versus QUESTRAN LIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLESEVELAM HYDROCHLORIDE versus QUESTRAN LIGHT.
COLESEVELAM HYDROCHLORIDE vs QUESTRAN LIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colesevelam hydrochloride is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, resulting in decreased serum LDL cholesterol. In diabetes, it improves glycemic control possibly by altering bile acid signaling via FXR and TGR5 receptors, affecting hepatic glucose production and incretin release.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation of bile acids and promoting conversion of cholesterol to bile acids in the liver.
3.75 g orally once daily or divided as 1.875 g twice daily with meals and liquid; maximum 4.375 g/day.
4 grams (one packet or one level scoop) orally once or twice daily, with a maximum of 24 grams per day. Dose may be increased by 4 grams daily at weekly intervals as needed.
None Documented
None Documented
Not applicable as colesevelam is not absorbed; it acts locally in the gastrointestinal tract.
Not applicable; cholesteryamine resin is not absorbed systemically; half-life refers to GI transit time (~2-4 hours).
Colesevelam is not absorbed systemically; it is excreted unchanged in the feces via biliary elimination. No renal excretion occurs.
Primarily fecal (as resin-bound bile acids); less than 0.05% renally excreted unchanged.
Category A/B
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant